首页> 美国卫生研究院文献>Oncotarget >Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice
【2h】

Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice

机译:HSF1的抑制抑制了体外肝癌细胞系的生长以及小鼠AKT驱动的肝癌发生

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Upregulation of the heat shock transcription factor 1 (HSF1) has been described as a frequent event in many cancer types, but its oncogenic role in hepatocellular carcinoma (HCC) remains poorly delineated. In the present study, we assessed the function(s) of HSF1 in hepatocarcinogenesis via in vitro and in vivo approaches. In particular, we determined the importance of HSF1 on v-Akt murine thymoma viral oncogene homolog (AKT)-induced liver cancer development in mice. We found that knockdown of HSF1 activity via specific siRNA triggered growth restraint by suppressing cell proliferation and inducing massive cell apoptosis in human HCC cell lines. At the molecular level, HSF1 inhibition was accompanied by downregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) cascade and related metabolic pathways. Most importantly, overexpression of a dominant negative form of HSF1 (HSF1dn) in the mouse liver via hydrodynamic gene delivery led to the inhibition of mouse hepatocarcinogenesis driven by overexpression of AKT. In human liver cancer specimens, we detected that HSF1 is progressively induced from human non-tumorous surrounding livers to HCC, reaching the highest expression in the tumors characterized by the poorest outcome (as defined by the length of patients’ survival). In conclusion, HSF1 is an independent prognostic factor in liver cancer and might represent an innovative therapeutic target in HCC subsets characterized by activation of the AKT/mTOR pathway.
机译:热休克转录因子1(HSF1)的上调已被描述为许多类型的癌症中的常见事件,但其在肝细胞癌(HCC)中的致癌作用仍然很难确定。在本研究中,我们通过体外和体内方法评估了HSF1在肝癌发生中的功能。特别是,我们确定了HSF1对v-Akt鼠胸腺瘤病毒致癌基因同源物(AKT)诱导的小鼠肝癌发展的重要性。我们发现通过特异性siRNA敲低HSF1活性可通过抑制细胞增殖并诱导人HCC细胞系中大量细胞凋亡来触发生长抑制。在分子水平上,HSF1抑制伴随着磷酸肌醇3-激酶(PI3K)/ AKT /哺乳动物雷帕霉素靶标(mTOR)级联和相关代谢途径的下调。最重要的是,通过流体动力学基因传递在小鼠肝脏中HSF1(HSF1dn)的显性阴性形式的过表达导致了由AKT过表达驱动的小鼠肝癌的抑制。在人类肝癌标本中,我们检测到HSF1是从人类非肿瘤性周围肝逐渐诱导成HCC,在以最差结果为特征的肿瘤中达到最高表达(由患者的生存时间定义)。总之,HSF1是肝癌的独立预后因素,可能代表以AKT / mTOR途径激活为特征的HCC亚组中的创新治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号